Abstract
NEXCREAM is developed with priority to overcome hand-foot syndrome (skin reactions on palms and feet) after therapy with so-called multikinase inhibitors. Our aim is new adverse reaction of modern oncology therapy from group of multikinase inhibitors ? so called targeted biological therapy (for example Nexavar from Bayer company).
This adverse drug reaction is called in scientific literature as HFSR ? hand-foot skin reaction (skin reaction on palms and feet). In a current time there is very limited evidence how we can treat or prevent it.
Product NEXCREAM was registered at SZU (National Institute of Public Health).